http://orcid.org/0000-0002-0351-4141
References
- Gordts PL, Nock R, Son NH, et al. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest. 2016;126(8):2855–2866.
- Sacks FM. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Curr Opin Lipidol. 2015;26(1):56–63.
- Norata GD, Tsimikas S, Pirillo A, et al. Apolipoprotein C-III: from pathophysiology to pharmacology. Trends Pharmacol Sci. 2015;36(10):675–687.
- Ooi EM, Barrett PH, Chan DC, et al. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond). 2008;114(10):611–624.
- Ramms B, Gordts P. Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism. Curr Opin Lipidol. 2018; 29(3):171–179.
- Juntti-Berggren L, Berggren PO. Apolipoprotein CIII is a new player in diabetes. Curr Opin Lipidol. 2017;28(1):27–31.
- Hokanson JE, Kinney GL, Cheng S, et al. Susceptibility to type 1 diabetes is associated with ApoCIII gene haplotypes. Diabetes. 2006;55(3):834–838.
- Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010;362(12):1082–1089.
- Perry RJ, Samuel VT, Petersen KF, et al. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014;510(7503):84–91.
- Kohan AB. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2015;22(2):119–125.
- Atzmon G, Rincon M, Schechter CB, et al. Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS Biol. 2006;4(4):e113.
- Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322(5908):1702–1705.
- TG and HDL Working Group of the Exome Sequencing Project NHL and Blood Institute, Crosby J, Peloso GM, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22–31.
- Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32–41.
- Avall K, Ali Y, Leibiger IB, et al. Apolipoprotein CIII links islet insulin resistance to beta-cell failure in diabetes. Proc Natl Acad Sci USA. 2015;112(20):E2611–E2619.
- Olofsson C, Anderstam B, Bragfors-Helin AC, et al. Effects of acute fructose loading on levels of serum uric acid-a pilot study. Eur J Clin Invest. 2019;49(1):e13040.
- Nicolay A, Lombard E, Arlotto E, et al. Evaluation of new apolipoprotein C-II and apolipoprotein C-III automatized immunoturbidimetric kits. Clin Biochem. 2006; 39(9):935–941.
- Tilly P, Sass C, Vincent-Viry M, et al. Biological and genetic determinants of serum apoC-III concentration: reference limits from the Stanislas Cohort. J Lipid Res. 2003; 44(2):430–436.
- Noma A, Hata Y, Goto Y. Quantitation of serum apolipoprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: reference values, and age- and sex-related differences. Clin Chim Acta. 1991;199(2):147–157.
- Orsi FA, Lijfering WM, Van der Laarse A, et al. Association of apolipoproteins C-I, C-II, C-III and E with coagulation markers and venous thromboembolism risk. CLEP. 2019;11:625–633.
- Desroches S, Ruel IL, Deshaies Y, et al. Kinetics of plasma apolipoprotein C-III as a determinant of diet-induced changes in plasma triglyceride levels. Eur J Clin Nutr. 2008;62(1):10–17.
- Ruhaak L, Van der Laarse A, Cobbaert C. Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. Ann Clin Biochem. 2019;56(3):338–356.